-
The Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.
published: 26 Jan 2017
-
Newly Diagnosed Multiple Myeloma | Diagnosis, Initial Treatment | ASCT, Maintenance Therapy, Goals
In the first section, hosted by Craig E. Cole, MD, Assistant Professor of Medicine, College of Human Medicine, Michigan State University, Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan, we discuss the diagnosis and initial treatment of multiple myeloma.
In the second section (36:02), hosted by Brandon J. Blue, MD, Assistant Professor, Malignant Hematology Department, Moffit Cancer Center, Tampa, Florida, we discuss autologous stem cell transplantation [ASCT], continuous or maintenance therapy, and treatment goals.
The Multiple Myeloma Research Foundation (MMRF) drives discoveries for new treatments, accelerates groundbreaking clinical trials and fuels the most robust data-driven initiatives in cancer research. Our goal is to accelerate a cure for each and every p...
published: 29 Apr 2022
-
The Multiple Myeloma Research Foundation – The Future
The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.
published: 12 Oct 2018
-
MMRF 25 Voices - Anne Quinn Young
Twenty-five years ago, multiple myeloma was a little-known cancer and a neglected disease. The MMRF and its founders set out to change that. MMRF Chief Mission Officer Anne Quinn Young takes us on a little journey in her #25Voices film, setting the stage for amazing progress and collaboration within the myeloma community over several decades. Since those early days, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. We will not stop until there is a cure for each and every patient. #MMRF25
published: 12 Jul 2023
-
Additional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma.
Click the links below for the full activity!
Online Accredit...
published: 03 May 2024
-
Research Program Updates | MMRF Virtual Lab
In this update, MMRF Chief Scientific Officer George Mulligan, Ph.D. discusses MMRF Virtual Lab – our shared online global data platform for the entire multiple #myeloma research community. All the data we generate through a variety of research programs including CoMMpass and Immune Atlas will ultimately be stored and shared with other researchers through the MMRF Virtual Lab.
Learn more about our work to drive more personalized treatment approaches: https://themmrf.org/finding-a-cure/personalized-treatment-approaches/
published: 30 Oct 2023
-
Genomics | High Impact Topic (HIT)
Hear how doctors can use genomic information from your myeloma cells to provide therapy that is tailored to your myeloma subtype.
published: 25 Jun 2021
-
MMRF Patient Stories: Gail
Gail is an attorney from Brooklyn who loves vintage clothes. As a refractory patient, her journey with myeloma has been particularly challenging. With the MMRF’s support, Gail received novel bispecific treatments using her own immune system to address multiple myeloma. “Never, never give up...words I live by.”
Follow us to hear other patient stories!
Facebook: https://www.facebook.com/theMMRF
Instagram: https://www.instagram.com/themmrf/
LinkedIn: https://www.linkedin.com/company/multiple-myeloma-research-foundation/
X, formerly known as Twitter: https://twitter.com/theMMRF
To learn more about our Patient Navigation Center: https://themmrf.org/support/patient-navigation-center/
To learn more about Myeloma Mentors: https://themmrf.org/support/myeloma-mentors/
published: 12 Sep 2023
-
FAQs on Autologous Stem Cell Transplantation
In our upcoming Livestream session, a myeloma health care team will answer questions about how autologous stem cell transplantation (ASCT) is used in treating multiple myeloma. Mark your calendar for May 6 at 4:00 PM ET and be sure to join us!
published: 07 May 2024
-
Fatal to Fearless: How Kathy Giusti and the MMRF changed the entire disease-fighting system
Kathy Giusti is a business leader and a healthcare disrupter. She is a two-time cancer survivor, having been diagnosed with multiple myeloma and breast cancer. Kathy co-founded the Multiple Myeloma Research Foundation (MMRF) where she served as CEO and President for nearly two decades. She also co-chaired the HBS Kraft Precision Medicine Accelerator, which she helped found as a Senior Fellow at Harvard Business School.
Kathy is recognized as a pioneer in precision medicine, having seen its vast potential in oncology and other diseases. She uses her patient experience and business acumen to drive science faster with innovative models across registries, big data, clinical trials, and venture. Kathy is a champion of patient engagement, encouraging each patient to take initiative to optimize ...
published: 11 Apr 2024
4:03
The Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and l...
The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.
https://wn.com/The_Multiple_Myeloma_Research_Foundation
The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.
- published: 26 Jan 2017
- views: 8843
1:10:32
Newly Diagnosed Multiple Myeloma | Diagnosis, Initial Treatment | ASCT, Maintenance Therapy, Goals
In the first section, hosted by Craig E. Cole, MD, Assistant Professor of Medicine, College of Human Medicine, Michigan State University, Karmanos Cancer Instit...
In the first section, hosted by Craig E. Cole, MD, Assistant Professor of Medicine, College of Human Medicine, Michigan State University, Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan, we discuss the diagnosis and initial treatment of multiple myeloma.
In the second section (36:02), hosted by Brandon J. Blue, MD, Assistant Professor, Malignant Hematology Department, Moffit Cancer Center, Tampa, Florida, we discuss autologous stem cell transplantation [ASCT], continuous or maintenance therapy, and treatment goals.
The Multiple Myeloma Research Foundation (MMRF) drives discoveries for new treatments, accelerates groundbreaking clinical trials and fuels the most robust data-driven initiatives in cancer research. Our goal is to accelerate a cure for each and every patient diagnosed with multiple myeloma. Learn more at https://themmrf.org/.
https://wn.com/Newly_Diagnosed_Multiple_Myeloma_|_Diagnosis,_Initial_Treatment_|_Asct,_Maintenance_Therapy,_Goals
In the first section, hosted by Craig E. Cole, MD, Assistant Professor of Medicine, College of Human Medicine, Michigan State University, Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan, we discuss the diagnosis and initial treatment of multiple myeloma.
In the second section (36:02), hosted by Brandon J. Blue, MD, Assistant Professor, Malignant Hematology Department, Moffit Cancer Center, Tampa, Florida, we discuss autologous stem cell transplantation [ASCT], continuous or maintenance therapy, and treatment goals.
The Multiple Myeloma Research Foundation (MMRF) drives discoveries for new treatments, accelerates groundbreaking clinical trials and fuels the most robust data-driven initiatives in cancer research. Our goal is to accelerate a cure for each and every patient diagnosed with multiple myeloma. Learn more at https://themmrf.org/.
- published: 29 Apr 2022
- views: 54983
3:40
The Multiple Myeloma Research Foundation – The Future
The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure....
The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.
https://wn.com/The_Multiple_Myeloma_Research_Foundation_–_The_Future
The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.
- published: 12 Oct 2018
- views: 4856
1:57
MMRF 25 Voices - Anne Quinn Young
Twenty-five years ago, multiple myeloma was a little-known cancer and a neglected disease. The MMRF and its founders set out to change that. MMRF Chief Mission ...
Twenty-five years ago, multiple myeloma was a little-known cancer and a neglected disease. The MMRF and its founders set out to change that. MMRF Chief Mission Officer Anne Quinn Young takes us on a little journey in her #25Voices film, setting the stage for amazing progress and collaboration within the myeloma community over several decades. Since those early days, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. We will not stop until there is a cure for each and every patient. #MMRF25
https://wn.com/Mmrf_25_Voices_Anne_Quinn_Young
Twenty-five years ago, multiple myeloma was a little-known cancer and a neglected disease. The MMRF and its founders set out to change that. MMRF Chief Mission Officer Anne Quinn Young takes us on a little journey in her #25Voices film, setting the stage for amazing progress and collaboration within the myeloma community over several decades. Since those early days, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. We will not stop until there is a cure for each and every patient. #MMRF25
- published: 12 Jul 2023
- views: 415
5:57
Additional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving...
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma.
Click the links below for the full activity!
Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma
Live or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma
https://wn.com/Additional_Advances_In_Multiple_Myeloma_Research_And_Clinical_Trials_With_Rahul_Banerjee,_Md,_Facp
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma.
Click the links below for the full activity!
Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma
Live or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma
- published: 03 May 2024
- views: 458
2:47
Research Program Updates | MMRF Virtual Lab
In this update, MMRF Chief Scientific Officer George Mulligan, Ph.D. discusses MMRF Virtual Lab – our shared online global data platform for the entire multiple...
In this update, MMRF Chief Scientific Officer George Mulligan, Ph.D. discusses MMRF Virtual Lab – our shared online global data platform for the entire multiple #myeloma research community. All the data we generate through a variety of research programs including CoMMpass and Immune Atlas will ultimately be stored and shared with other researchers through the MMRF Virtual Lab.
Learn more about our work to drive more personalized treatment approaches: https://themmrf.org/finding-a-cure/personalized-treatment-approaches/
https://wn.com/Research_Program_Updates_|_Mmrf_Virtual_Lab
In this update, MMRF Chief Scientific Officer George Mulligan, Ph.D. discusses MMRF Virtual Lab – our shared online global data platform for the entire multiple #myeloma research community. All the data we generate through a variety of research programs including CoMMpass and Immune Atlas will ultimately be stored and shared with other researchers through the MMRF Virtual Lab.
Learn more about our work to drive more personalized treatment approaches: https://themmrf.org/finding-a-cure/personalized-treatment-approaches/
- published: 30 Oct 2023
- views: 305
4:55
Genomics | High Impact Topic (HIT)
Hear how doctors can use genomic information from your myeloma cells to provide therapy that is tailored to your myeloma subtype.
Hear how doctors can use genomic information from your myeloma cells to provide therapy that is tailored to your myeloma subtype.
https://wn.com/Genomics_|_High_Impact_Topic_(Hit)
Hear how doctors can use genomic information from your myeloma cells to provide therapy that is tailored to your myeloma subtype.
- published: 25 Jun 2021
- views: 942
3:48
MMRF Patient Stories: Gail
Gail is an attorney from Brooklyn who loves vintage clothes. As a refractory patient, her journey with myeloma has been particularly challenging. With the MMRF’...
Gail is an attorney from Brooklyn who loves vintage clothes. As a refractory patient, her journey with myeloma has been particularly challenging. With the MMRF’s support, Gail received novel bispecific treatments using her own immune system to address multiple myeloma. “Never, never give up...words I live by.”
Follow us to hear other patient stories!
Facebook: https://www.facebook.com/theMMRF
Instagram: https://www.instagram.com/themmrf/
LinkedIn: https://www.linkedin.com/company/multiple-myeloma-research-foundation/
X, formerly known as Twitter: https://twitter.com/theMMRF
To learn more about our Patient Navigation Center: https://themmrf.org/support/patient-navigation-center/
To learn more about Myeloma Mentors: https://themmrf.org/support/myeloma-mentors/
https://wn.com/Mmrf_Patient_Stories_Gail
Gail is an attorney from Brooklyn who loves vintage clothes. As a refractory patient, her journey with myeloma has been particularly challenging. With the MMRF’s support, Gail received novel bispecific treatments using her own immune system to address multiple myeloma. “Never, never give up...words I live by.”
Follow us to hear other patient stories!
Facebook: https://www.facebook.com/theMMRF
Instagram: https://www.instagram.com/themmrf/
LinkedIn: https://www.linkedin.com/company/multiple-myeloma-research-foundation/
X, formerly known as Twitter: https://twitter.com/theMMRF
To learn more about our Patient Navigation Center: https://themmrf.org/support/patient-navigation-center/
To learn more about Myeloma Mentors: https://themmrf.org/support/myeloma-mentors/
- published: 12 Sep 2023
- views: 3536746
47:18
FAQs on Autologous Stem Cell Transplantation
In our upcoming Livestream session, a myeloma health care team will answer questions about how autologous stem cell transplantation (ASCT) is used in treating m...
In our upcoming Livestream session, a myeloma health care team will answer questions about how autologous stem cell transplantation (ASCT) is used in treating multiple myeloma. Mark your calendar for May 6 at 4:00 PM ET and be sure to join us!
https://wn.com/Faqs_On_Autologous_Stem_Cell_Transplantation
In our upcoming Livestream session, a myeloma health care team will answer questions about how autologous stem cell transplantation (ASCT) is used in treating multiple myeloma. Mark your calendar for May 6 at 4:00 PM ET and be sure to join us!
- published: 07 May 2024
- views: 418
6:47
Fatal to Fearless: How Kathy Giusti and the MMRF changed the entire disease-fighting system
Kathy Giusti is a business leader and a healthcare disrupter. She is a two-time cancer survivor, having been diagnosed with multiple myeloma and breast cancer. ...
Kathy Giusti is a business leader and a healthcare disrupter. She is a two-time cancer survivor, having been diagnosed with multiple myeloma and breast cancer. Kathy co-founded the Multiple Myeloma Research Foundation (MMRF) where she served as CEO and President for nearly two decades. She also co-chaired the HBS Kraft Precision Medicine Accelerator, which she helped found as a Senior Fellow at Harvard Business School.
Kathy is recognized as a pioneer in precision medicine, having seen its vast potential in oncology and other diseases. She uses her patient experience and business acumen to drive science faster with innovative models across registries, big data, clinical trials, and venture. Kathy is a champion of patient engagement, encouraging each patient to take initiative to optimize their own care.
Kathy has been named one of Time magazine’s 100 Most Influential People in the World and was ranked #19 on Fortune’s list of the World’s 50 Greatest Leaders. She has been featured in the Wall Street Journal, the New York Times, and Fast Company, and on the Today Show, Bloomberg, and CNN.
In 1998, soon after being diagnosed with multiple myeloma and given three years to live, Kathy founded the MMRF with her identical twin sister, Karen Andrews. At the time, there were no new treatments in the multiple myeloma pipeline. Having worked in leadership positions in the pharmaceutical industry, Kathy understood the industry’s scientific capabilities. But as a patient, Kathy had experienced the broken, dysfunctional healthcare system—and was motivated to use her knowledge and experience to change it. Read our Founders' story: https://themmrf.org/about/our-founders/
Under Giusti, the MMRF raised more than $500 million to fund research and has established partnerships and collaborative research models in precision medicine, including the Multiple Myeloma Research Consortium (MMRC), which has conducted nearly 100 trials, the MMRF CoMMpass™ study, CureCloud®, the Right Track, and the Myeloma Investment Fund. Since the MMRF was founded, 15+ drugs have been approved to treat multiple myeloma and many clinical trials are underway. These efforts have accelerated the pace at which treatments are brought to patients and have more than tripled patients’ survival.
As Co-Chair of the Harvard Business School Kraft Precision Medicine Accelerator, a $20 million program endowed by Robert Kraft and the Kraft Family Foundation, Kathy convened more than 300 leaders from throughout the healthcare ecosystem. She identified and published best practices for accelerating cures and created The Kraft Accelerator Playbook for Cures to help organizations across all disease states develop strategies to accelerate cures. Kathy continues to work with CEOs from disease-focused organizations to address their most important challenges and share solutions.
Kathy was appointed to President Obama’s Precision Medicine Initiative Working Group and served as an advisor to the Biden Moonshot program. She was named to the President’s Council of Advisors on Science and Technology (PCAST), the National Cancer Advisory Board (NCAB), and the National Cancer Policy Board (NCPB). Kathy serves on the Board of Directors for EQRx and the MMRF. She serves on the Verily Advisory Board, the FasterCures Non-Profit Council, and the Harvard Business School Health Advisory Board. She is highly published with articles in the Harvard Business Review, Time, Forbes.com, STAT, and Nature.
Kathy received her MBA in general management from Harvard Business School and holds a BS and an honorary doctorate from the University of Vermont.
https://wn.com/Fatal_To_Fearless_How_Kathy_Giusti_And_The_Mmrf_Changed_The_Entire_Disease_Fighting_System
Kathy Giusti is a business leader and a healthcare disrupter. She is a two-time cancer survivor, having been diagnosed with multiple myeloma and breast cancer. Kathy co-founded the Multiple Myeloma Research Foundation (MMRF) where she served as CEO and President for nearly two decades. She also co-chaired the HBS Kraft Precision Medicine Accelerator, which she helped found as a Senior Fellow at Harvard Business School.
Kathy is recognized as a pioneer in precision medicine, having seen its vast potential in oncology and other diseases. She uses her patient experience and business acumen to drive science faster with innovative models across registries, big data, clinical trials, and venture. Kathy is a champion of patient engagement, encouraging each patient to take initiative to optimize their own care.
Kathy has been named one of Time magazine’s 100 Most Influential People in the World and was ranked #19 on Fortune’s list of the World’s 50 Greatest Leaders. She has been featured in the Wall Street Journal, the New York Times, and Fast Company, and on the Today Show, Bloomberg, and CNN.
In 1998, soon after being diagnosed with multiple myeloma and given three years to live, Kathy founded the MMRF with her identical twin sister, Karen Andrews. At the time, there were no new treatments in the multiple myeloma pipeline. Having worked in leadership positions in the pharmaceutical industry, Kathy understood the industry’s scientific capabilities. But as a patient, Kathy had experienced the broken, dysfunctional healthcare system—and was motivated to use her knowledge and experience to change it. Read our Founders' story: https://themmrf.org/about/our-founders/
Under Giusti, the MMRF raised more than $500 million to fund research and has established partnerships and collaborative research models in precision medicine, including the Multiple Myeloma Research Consortium (MMRC), which has conducted nearly 100 trials, the MMRF CoMMpass™ study, CureCloud®, the Right Track, and the Myeloma Investment Fund. Since the MMRF was founded, 15+ drugs have been approved to treat multiple myeloma and many clinical trials are underway. These efforts have accelerated the pace at which treatments are brought to patients and have more than tripled patients’ survival.
As Co-Chair of the Harvard Business School Kraft Precision Medicine Accelerator, a $20 million program endowed by Robert Kraft and the Kraft Family Foundation, Kathy convened more than 300 leaders from throughout the healthcare ecosystem. She identified and published best practices for accelerating cures and created The Kraft Accelerator Playbook for Cures to help organizations across all disease states develop strategies to accelerate cures. Kathy continues to work with CEOs from disease-focused organizations to address their most important challenges and share solutions.
Kathy was appointed to President Obama’s Precision Medicine Initiative Working Group and served as an advisor to the Biden Moonshot program. She was named to the President’s Council of Advisors on Science and Technology (PCAST), the National Cancer Advisory Board (NCAB), and the National Cancer Policy Board (NCPB). Kathy serves on the Board of Directors for EQRx and the MMRF. She serves on the Verily Advisory Board, the FasterCures Non-Profit Council, and the Harvard Business School Health Advisory Board. She is highly published with articles in the Harvard Business Review, Time, Forbes.com, STAT, and Nature.
Kathy received her MBA in general management from Harvard Business School and holds a BS and an honorary doctorate from the University of Vermont.
- published: 11 Apr 2024
- views: 498